CVS Health Corporation CVS
Healthcare · Healthcare Plans · United States · S&P 500
Based on the available data, CVS Health Corporation gets an algorithmic score of 57/100. It trades at 87.10 $, with a sideways/transition technical trend (RSI 35.8) and 31.2% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (7.0%).
- Low valuation (P/E 10.2).
- Low beta (0.32): defensive profile.
- Meaningful dividend (3.05%).
Weaknesses
- Thin net margin (1.2%): vulnerable to costs.
Fundamentals
| P/E | 22.98 |
| Forward P/E | 10.21 |
| PEG | 0.21 |
| P/B | 1.40 |
| EV/EBITDA | 10.43 |
| P/S | 0.27 |
| ROE % | 6.21 |
| ROA % | 2.97 |
| Gross margin % | 13.65 |
| Operating margin % | 3.86 |
| Net margin % | 1.18 |
| Revenue growth % (y/y) | 7.10 |
| Earnings growth % (y/y) | 188.80 |
| Revenue CAGR % | 7.63 |
| Earnings CAGR % | -25.70 |
| Debt/Equity % | 95.50 |
| Current ratio | 0.87 |
| FCF yield % | 7.01 |
| Dividend yield % | 3.05 |
| Payout % | 70.18 |
Returns
| 1 month | -6.4 % |
| 3 months | -15.3 % |
| 6 months | +26.1 % |
| YTD | +11.2 % |
| 1 year | +18.6 % |
| 3 years | +37.3 % |
| 5 years | +22.5 % |
Risk
| 1-year volatility | 31.2 % |
| Beta | 0.32 |
| 5-year max drawdown | -56.8 % |
| Sharpe 1A | 0.58 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.